Lack of dose-response with pancrease MT for the treatment of exocrine pancreatic insufficiency in adults

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 981-986

  Opekun Jr , A R ^a,c   Sutton Jr , F M ^a   Graham, D Y ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FECES LIPID; MICROSPHERE; PANCREAS ENZYME; PANCRELIPASE; PLACEBO; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; DRUG CAPSULE; ENTERIC COATED TABLET; FECES ANALYSIS; HUMAN; ORAL DRUG ADMINISTRATION; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 9844222492     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00245.x     Document Type: Article

References (45)

1. DiMagno EP. Medical treatment of pancreatic insufficiency. Mayo Clin Proc 1979; 54: 435-42.
2. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986; 251: G475-80.
3. Graham DY. Treatment of steatorrhea in chronic pancreatitis. HospPract 1986:21: 125-9.
4. Lebenthal E, Rolston DD, Holsclaw DS. Enzyme therapy for pancreatic insufficiency: present status and future needs. Pancreas 1994; 9: 1-12.
5. Heizer WD, Cleaveland CR, Iber FL. Gastric inactivation of pancreatic supplements. Bull Johns Hopkins Hosp 1965; 116: 261-70.
6. Bruno MJ, Haverkort EB, Tytgat GN, van Leeuwen DJ. Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment. Am J Gastroenterol 1995; 90: 1383-93.
7. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994; 34: 158-66.
8. Graham DY. Ins and outs of pancreatic enzymes and adjuvant therapies. J Pediatr Gastroenterol Nutr 1984; 3(Suppl. 1): 120-6.
9. Heijerman HG, Lamers CB, Dijkman JH, Bakker W. Ranitidine compared with the dimethylprostaglandin E2 analogue enprostil as adjunct to pancreatic enzyme replacement in adult cystic fibrosis. Scand J Gastroenterol 1990; 178(Suppl.): 2631.
10. Graham DY. Enzyme replacement therapy of exocrine pancreatic insufficiency in man. Relations between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts. N Engl J Med 1977; 296: 1314-7.
11. Guarner L, Rodriguez R, Guamer F, Malagelada JR. Fate of oral enzymes in pancreatic insufficiency. Gut 1993; 34: 708-12.
12. Delchier JC, Vidon N. Saint-Marc Girardin MF, Soûle JC, Moulin C, Huchet B, Zylberberg P. Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations. Aliment Pharmacol Ther 1991; 5: 365-78.
13. Lancellotti L, Cabrini G, Zanolla L, Mastella G. High- versus low-lipase acid-resistant enzyme preparations in cystic fibrosis: a crossover randomized clinical trial. J Pediatr Gastroenterol Nutr 1996; 22: 73-8.
14. Kuhnelt P, Mundlos S, Adler G. Effect of pellet size of a pancreas enzyme preparation on duodenal lipolytic activity. Z Gastroenterol 1991:29:417-21.
15. Adler G, Mundlos S. Kuhnelt P, Dreyer E. New methods for assessment of enzyme activity: do they help to optimize enzyme treatment? Digestion 1993; 54(Suppl. 2): 3-9.
16. Dutta SK, Rubin J, Harvey J. Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency. Gastroenterol 1983; 84: 476-82.
17. Graham DY. An enteric-coated pancreatic enzyme preparation that works. Dig Dis Sei 1979; 24: 906-9.
18. Graham DY. Pancreatic enzyme replacement: the effect of antacids or cimetidine. Dig Dis Sei 1982; 27: 485-90.
19. Graham DY, Sackman JVV. Mechanism of increase in steatorrhea with calcium and magnesium in exocrine pancreatic insufficiency: an animal model. Gastroenterol 1982; 83:638-44.
20. Braga M, Zerbi A, Malesci A, Dal Cin S, Valentin! A, Tacconi M, Erenbourg L, Paganelli M, Di Carlo V. Fat absorption and gastroenteric pH profile in postsurgical pancreatic insufficiency: role of the association of H2-rcceptor antagonists with pancreatic enzymes. Pancreas 1993; 8: 494-8.
21. Lamers CB, Jansen JB. Omeprazole as adjunct to enzyme replacement in severe pancreatic insufficiency. Br Med J 1986; 293: 994.
22. Lankisch PG, Lembcke B, Goke B, Creutzfeldt W. Therapy of pancreatogenic steatorrhoea: does acid protection of pancreatic enzymes offer any advantage? Z Gastroenterol 1986; 24: 753-7.
23. Hubbard VS, Dünn GD, Lester LA. Effectiveness of cimetidine as an adjunct to supplemental pancreatic enzymes in patients with cystic fibrosis. Am J Clin Nutr 1980; 33: 2281-6.
24. Durie PR, Bell L, Linton W, Corey ML, Forstner GG. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 1980; 21: 778-86.
25. Cox KL, Isenberg JN, Osher AB, Dooley RR.r The effect of cimetidine on maldigestion in cystic fibrosis. J Pediatr 1979; 94: 488-92.
26. Gow R, Bradbear R, Francis P, Shepherd R. Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine. Lancet 1981; 2: 1071-1.
27. Regan FT, Malagelada JR, DiMagno EP, Glanzman SL, Go VL. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med 1977: 297: 854-8.
28. Heijerman HG, Lamers CB, Bakker W, Dijkman JH. Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas. Dig Dis Sei 1993; 38: 1-6.
29. Heijerman HG, Lamers CB, Bakker W. Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. Ann Intern Med 1991; 114: 200-1.
30. Bruno MJ, Rauws EA, Hoek FJ, Tytgat GN. Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. Dig Dis Sei 1994; 39: 988-92.
31. Marotta F, O'Keefe SJ, Marks IN, Girdwood A, Young G. Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating. Dig Dis Sei 1989:34:456-61.
32. Sackman JVV, Smith KE, Graham DY. Does mixing pancreatic enzyme microspheres (Pancrease) with food damage the enteric coating? J Pediatr Gastroenterol Nutr 1982; 1: 333-5.
33. Walters MP, Littlewood JM. Pancreatin preparations used in the treatment of cystic fibrosis-lipase content and in vitro release. Aliment Pharmacol Ther 1996; 10: 433-40.
34. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. J Am Med Assoc 1990; 263: 2459-61.
35. O'Hare MM, McMaster C, Dodge JA. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. J Pediatr Gastroenterol Nutr 1995; 21: 59-63.
36. Pap A, Varro V. Proteolytic inactivation of lipase as a possible cause of the uneven results obtained with enzyme substitution in pancreatic insufficiency. Hepatogastroenterol 1984: 31: 47-50.
37. Lebenthal E. High strength pancreatic exocrine enzyme capsules associated with colonie strictures in patients with cystic fibrosis: 'more is not necessarily better'. J Pediatr Gastroenterol Nutr 1994; 18: 423-5.
38. Abiin DS, Ziegler M. Ulcerative type of colitis associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis. Pediatr Radiol 1995:25:113-6.
39. Davidson GP, Hassel FM, Crozier D, Corey M, Forstner GG. latrogenic hyperuricemia in children with cystic fibrosis. J Pediatr 1978; 93: 976-8.
40. Stapleton FB, Kennedy J, Nousia-Arvanitakis S, Linshaw MA. Hypcruricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med 1976; 295: 246-8.
41. Smyth RL, Ashby D, O'Hea U, Burrows E, Lewis P, van Velzen D, Dodge JA. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995; 346: 1247-51.
42. Can KH, Heijerman HG, Gcus VVP, Bakker W, Lamers CB. Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients. Aliment Pharmacol Ther 1994; 8: 603-7.
43. Cox KL, Isenberg JN, Ament ME. Gastric acid hypersécrétion in cystic fibrosis. J Pediatr Gastroenterol Nutr 1982; 1:55965.
44. Dutta SK, Hubbard VS. Appler M. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis. Dig Dis Sei 1988; 33: 1237-44.
45. Regan PT, Malagelada JR, DiMagno EP, Go VL. Postprandial gastric function in pancreatic insufficiency. Gut 1979; 20: 249-54.